Genprex, Inc. reported a net loss of $16.2 million for the year ended December 31, 2025, a decrease of 23% compared to a net loss of $21.1 million for the year ended December 31, 2024. The decrease in net loss was attributed to the implementation of expense reduction strategies, including reduced travel expenses, fewer professional service providers, and a decrease in overall company staff from 15 to 13 employees. The company has not generated any revenue from product sales to date and anticipates continuing losses for the foreseeable future as it continues to develop and seek regulatory approvals for its product candidates.

Research and development expenses totaled $9.4 million for 2025, a decrease of 11% from $10.5 million in 2024. This reduction was primarily due to the closure of the Acclaim-2 clinical trial, differences in enrollment of the Acclaim-1 and Acclaim-3 clinical trials, and the implementation of expense reduction strategies. General and administrative expenses decreased by 43% to $6.1 million in 2025, compared to $10.6 million in the previous year. This decrease was mainly due to one-time charges associated with the separation of a former executive, a reduction in share-based compensation, and the implementation of expense reduction strategies.

The company's lead oncology drug candidate, REQORSA, is currently in Phase 2a expansion of the Acclaim-1 clinical trial for Non-Small Cell Lung Cancer (NSCLC) and Phase 2 expansion of the Acclaim-3 clinical trial for Small Cell Lung Cancer (SCLC). Genprex is also advancing its diabetes gene therapy, GPX-002, through preclinical studies. In February 2025, the company formed a wholly-owned subsidiary, Convergen Biotech, Inc., to facilitate the potential separation of its diabetes clinical development program.

Genprex is actively working to address material weaknesses in its internal control over financial reporting, including implementing new accounting software, processes, and workflows to further segregate duties among limited accounting staff. The company expects its existing cash to fund operations into the second quarter of 2027, but will need additional fundraising activities and cash on hand by such time. As of December 31, 2025, Genprex had $7.8 million in cash and cash equivalents.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies for cancer and diabetes. Its oncology platform uses non-viral lipid nanoparticles to deliver tumor suppressor genes, aiming to treat lung cancers and other solid tumors. The company's diabetes program focuses on gene therapies to regenerate insulin-producing cells. Its business model centers on innovative gene delivery systems, clinical trials, and strategic collaborations.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.